Reshaping the narrative on biopharma innovation with BIO Board Chair Dr. Ted Love

Mainstage at the GA Life Sciences Summit

Dovetailing closely on access, advocacy, policy and innovation, BIO Board Chair and founder of Global Blood Therapeutics Dr. Ted Love discussed his mission oriented journey in the life sciences in the day’s keynote. This work continues with the need to reshape the narrative around biopharma innovation, access, cost and value.

“Drug cost is not a singular item,” Dr. Love told GRA Senior Advisor Greg Vaughn, MD in their post remarks chat. “We need to get copays out of the system and stop blocking egregious things we do to discourage patients from taking medicines.”

Our recent weekly bioBEAT summarized Dr. Love’s keynote thusly: 

“BIO Board Chair Dr. Ted Love founded a company (Global Blood Therapeutics—since acquired by Pfizer ) to develop treatments for sickle cell disease, so he is solidly grounded in the biopharma space. However, he’s enthusiastic about biotech’s potential to help achieve a wide range of societal goals. At Georgia Bio’s Life Sciences Summit this week, Ted spoke about the importance of communicating biotech’s full potential and opening minds to the promise of innovation.

“‘Showing the public how we change lives through innovations is a huge task that we must all embrace!’ he said in his remarks. ‘But, we can do this by telling everyone we talk to [that] biotechnology is our only hope – to fight egregious diseases and future pandemics, to produce clean energy to fight climate change, to solve food insecurity , and to provide biodefense to keep us all secure.’

“Ted shared a story about his own daughter’s (Alex) skepticism toward the biopharma industry—until she spent one summer working at Global Blood Therapeutics and saw firsthand how impactful the company’s work could be for patients. ‘Perhaps we can learn a lesson from my experience with Alex when it comes to reframing the narrative of our industry,’ he said.

“‘We need to increase awareness of what we are achieving in our society,’ he added, ‘by telling our powerful stories of innovation and standing up for science. It will require highlighting the possibilities of mRNA vaccines, gene therapy, crop editing , and the many other amazing technologies that we are investing in. mRNA took years and years to develop, but it arrived in time to treat Covid-19.’ Read Ted’s full remarks here.

Mainstage at the GA Life Sciences Summit
February 20, 2026
Recognition highlights Brookhaven’s commitment to life sciences growth and biomanufacturing readiness Brookhaven, GA, Feb. 18, 2026 – The City of Brookhaven has been designated a BioReady Gold Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady Community program evaluates a community’s preparedness to support life sciences development across key areas, including zoning and permitting, utilities and infrastructure, workforce readiness, and coordination among local government and economic development partners. The Gold distinction represents a high level of readiness and alignment with industry needs. “Achieving Gold BioReady status underscores Brookhaven’s commitment to being a competitive destination for life sciences innovation and manufacturing,” said Aaron Szarowicz, City of Brookhaven Economic Development Director. “This designation reflects the intentional investments and partnerships we’ve built to support companies as they scale and create high-quality jobs in our community.” Brookhaven’s BioReady assessment highlighted the City’s modern infrastructure, strategic location within metro Atlanta, access to a skilled workforce, and collaborative approach between City leadership, regional partners, and the business community. Together, these assets position Brookhaven to support companies across the life sciences value chain—from research and development to scale-up and manufacturing. The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-zoned sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Brookhaven to compete more effectively for private investment and job creation. Georgia Life Sciences works to advance innovation, strengthen the workforce pipeline, and grow Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. For more information on the non-profit, membership-based organization, visit www.galifesciences.org . For more information about Brookhaven’s economic development initiatives, visit www.BrookhavenGA.gov/EconDev . ### Media Contact: Ann Marie Quill, Assistant Communications Director 404-205-3832 AnnMarie.Quill@BrookhavenGA.gov
February 18, 2026
Georgia Life Sciences Releases “Pathways & Partnerships: A Roadmap for Georgia’s Life Sciences Sector”
February 17, 2026
by Maria Saporta February 9, 2026
MORE POSTS